Breaking the cycle: should we target inflammation, fibrosis, or both?

Area of Science:

• Immunology
• Pathology
• Pulmonology

Background:

• Chronic inflammatory and autoimmune diseases can lead to irreversible fibrosis, impairing organ function.
• The optimal therapeutic strategy (targeting inflammation, fibrosis, or both) remains a critical question for disease management.
• Interstitial lung diseases (ILDs) provide a model for studying inflammation-fibrosis interplay.

Purpose of the Study:

• To explore the relationship between inflammation and fibrosis in lung diseases.
• To evaluate therapeutic strategies targeting cytokine pathways and B lymphocytes in systemic sclerosis (SSc), idiopathic pulmonary fibrosis (IPF), and rheumatoid arthritis (RA).
• To identify potential pathways for restoring tissue homeostasis and improving functional outcomes.

Main Methods:

• Review of clinical and translational studies on human ILD tissue.
• Analysis of molecular and proteomic data implicating immune cells (macrophages, B cells) in fibrogenesis.
• Examination of data from molecular interventions targeting cytokine pathways and B lymphocytes.

Main Results:

• Immune system components, including specific macrophage populations and B cells producing autoantibodies, are implicated in fibrogenesis.
• Interventions targeting cytokine pathways and B lymphocytes show potential in modulating clinical, functional, cellular, and molecular outcomes.
• Mechanistic links between inflammation and fibrosis in human diseases are beginning to be elucidated.

Conclusions:

• Understanding the interplay between inflammation and fibrosis is essential for developing targeted therapies.
• Further granular clinical outcomes, biomarker data, and assay standardization are needed to optimize therapeutic strategies.
• Future research may lead to improved treatments for restoring tissue homeostasis and preserving organ function in fibrotic diseases.